FTI Advances delivers rigorous Permitted Daily Exposure (PDE) certification for pharmaceutical cleaning validation — prepared by qualified toxicologists and accepted by EMA, FDA, WHO, and India's CDSCO.
The Permitted Daily Exposure (PDE) is a substance-specific dose, expressed in mg/day, that is unlikely to cause an adverse effect if an individual is exposed at or below this dose every day for a lifetime. It is derived from the compound's toxicological and pharmacological profile — incorporating the most sensitive adverse effect, the relevant point of departure (NOAEL or LOAEL), and a series of uncertainty factors to account for interspecies variation, intraspecies variability, and data gaps.
EMA mandated PDE-based cleaning validation in 2014, replacing arbitrary historical limits. The PDE is used to calculate the Maximum Allowable Carryover (MACO) — the maximum residue of a previous API that is acceptable in the next product. MACO drives your analytical cleaning limits (swab limits and rinse water limits) in the cleaning validation protocol.
PDE certification from a qualified toxicologist is now required by EMA, PIC/S, WHO-GMP, and India's revised Schedule M. Without valid PDE certification, pharmaceutical manufacturers cannot demonstrate compliant cleaning validation to regulatory inspectors.
Beyond API cleaning validation, PDE certification is also required for residual solvent control per ICH Q3C. Class 1 solvents (known human carcinogens, to be avoided), Class 2 solvents (non-genotoxic animal carcinogens or possible human hazards), and Class 3 solvents (low toxic potential) all have established PDE values in the ICH Q3C guideline.
For novel solvents not listed in ICH Q3C, or for solvents used in processes where the ICH Q3C limits may not be applicable, FTI Advances provides qualified toxicologist derivation of custom PDE values — ensuring your residual solvent limits are scientifically justified and defensible in regulatory submissions.
ICH Q3D establishes Permitted Daily Exposures for elemental impurities (heavy metals and other inorganic impurities) in pharmaceutical drug products. PDEs are provided for oral, parenteral, and inhalation routes for 24 elements of toxicological concern. For less common elements or novel formulation routes, FTI Advances provides qualified toxicologist PDE derivation aligned with ICH Q3D methodology.
Our ICH Q3D PDE certification services are particularly relevant for novel drug delivery systems, parenteral products with complex container closure systems, and inhalation products where elemental impurity PDE limits for the inhalation route may be significantly lower than oral route PDEs.
FTI Advances operates a streamlined PDE certification process designed to minimise client effort while ensuring scientific rigour. Clients submit the API name, CAS number, molecular structure, route of administration, and any internal pharmacological or toxicological data. Our qualified toxicologist team conducts the full assessment and delivers the completed PDE certification report within 5–7 business days for standard molecules.
The PDE certification report includes: a structured literature review summary; pharmacological and pharmacokinetic data overview; identification of the critical effect and point of departure; uncertainty factor application with individual justification; final PDE value for relevant administration routes; MACO calculation template; regulatory compliance certification (EMA, FDA, WHO, Schedule M); and the qualified toxicologist's signed declaration with credentials.
Biologics, biosimilars, and novel biological entities present unique challenges for PDE certification due to their complex mechanism of action, species-specific pharmacology, and limited traditional toxicological datasets. FTI Advances' qualified toxicologists have extensive experience in PDE derivation for monoclonal antibodies, recombinant proteins, oligonucleotides, and advanced therapy medicinal products (ATMPs).
For biologics, our PDE certification approach leverages pharmacological activity-based PDE derivation (ADE-PD approach), TTC (Threshold of Toxicological Concern) principles where applicable, and read-across from structurally or mechanistically related molecules — ensuring scientifically justified limits even where traditional animal toxicity data is absent or limited.
India's revised Schedule M under the Drugs and Cosmetics Act now requires Indian pharmaceutical manufacturers to establish and document PDE/HBEL values for all APIs manufactured on shared equipment. CDSCO inspectors verify this documentation during GMP audits, and failure to produce valid PDE certification from a qualified toxicologist is now a citable GMP deficiency.
FTI Advances, incubated at NFSU Ahmedabad, is India's specialist PDE certification provider for domestic Schedule M compliance. Our reports are structured to simultaneously satisfy Schedule M, EMA, WHO-GMP, and USFDA requirements — ensuring Indian manufacturers are fully prepared for both domestic and export market inspections.
When selecting a PDE certification toxicologist in India, regulatory inspectors expect to see documented evidence of the expert's qualifications. EMA's Q&A on health-based exposure limits is explicit: the toxicologist must have adequate expertise in toxicology and pharmacology, familiarity with pharmaceuticals, and experience specifically in health-based exposure limit derivation. FTI Advances' PDE certification toxicologist team meets all these criteria — with credentials verifiable in our supplier qualification package.
Our PDE certification india services cover all molecule classes and all regulatory routes. For PDE value calculation india involving novel APIs with limited toxicological datasets, our qualified toxicologists employ read-across methodology, computational toxicology tools, and structural activity relationship (SAR) analysis to derive scientifically justified PDE values — even where traditional NOAEL data is unavailable. This capability is particularly important for early-stage pharmaceutical development programmes where PDE certification must be established before first-in-human studies.
FTI Advances is also a trusted provider of EMA PDE report india services, preparing reports in the exact format expected by European GMP inspectors — including the mandatory uncertainty factor table, point of departure identification, and route-specific PDE calculations for oral, parenteral, and inhalation exposure routes. Our PDE ADE certificate provider India team has a track record of zero critical observations across multiple EMA GMP inspections where our PDE certificates were under review.
A credible PDE certification report is a structured scientific document — not a certificate that can be generated by a template. Regulatory inspectors, particularly those conducting EMA GMP site visits and USFDA Pre-Approval Inspections, are well-versed in identifying reports that lack genuine scientific rigour. When FTI Advances provides PDE certification by a qualified toxicologist, the report includes a complete literature review, a clearly identified critical effect with data tables, individually justified uncertainty factors, and a final PDE value with route-specific calculations. The toxicologist's academic credentials and professional certifications are included in the report itself — giving inspectors and your quality team full visibility into the qualifications behind the science.
FTI Advances has designed a simple, efficient process for pharmaceutical manufacturers who need PDE certification from a qualified toxicologist in India. You submit your API name, CAS number, and administration route — and our expert team manages the entire assessment from literature search through final report preparation. The completed PDE certification document is delivered in PDF and Word format within five to seven business days, ready for direct integration into your cleaning validation master plan and regulatory submission dossier. Every report is reviewed by a senior toxicologist before delivery, and our team provides post-issuance support for any regulatory queries that may arise during your next GMP inspection.
India's pharmaceutical industry supplies approximately 20% of the world's generic medicines — and maintaining access to regulated export markets depends on flawless GMP documentation. The revised Schedule M, EMA GMP requirements, and USFDA cleaning validation guidance all converge on a single expectation: that every API manufactured on shared equipment must have a PDE or ADE value derived by a qualified expert. FTI Advances was established to meet precisely this need — providing pharmaceutical exporters across India with access to world-class PDE certification toxicologist expertise at competitive pricing, without compromising on the scientific standards that global regulatory agencies demand.
Audit-ready PDE certification delivered in 5–7 days. Accepted by EMA, FDA, CDSCO, and WHO. Competitive pricing with bulk discounts for 10+ molecules.
Request PDE Certification →Complete permitted daily exposure certification — all routes, all regulatory frameworks, by qualified toxicologists.
PDE derivation for pharmaceutical APIs per EMA Guideline EMA/CHMP/CVMP/SWP/169430/2012 — all routes covered.
PDE certification for residual solvents — standard ICH Q3C limits and custom derivation for novel solvents.
PDE values for elemental impurities per ICH Q3D — oral, parenteral, and inhalation routes.
PDE certification for biologics, biosimilars, and ATMPs using pharmacological activity-based derivation methodology.
Direct derivation of cleaning validation acceptance criteria from your PDE certification values.
PDE certification structured specifically for India's revised Schedule M CDSCO inspection requirements.
HBEL (Health-Based Exposure Limit) is the overarching term covering all types of health-based limits including PDE (patient safety, from EMA terminology), ADE (patient safety, from ISPE/FDA terminology), and OEL (worker safety). PDE and ADE are functionally equivalent; HBEL is the category containing both.
PDE values do not have a fixed expiry date, but EMA Q&A 2018 requires periodic review — typically every 3 years or when new relevant toxicological data is published. FTI Advances provides periodic review services to keep your PDE certification current.
Yes. All FTI Advances PDE certification reports are structured to comply with India's revised Schedule M simultaneously with EMA, FDA, and WHO-GMP requirements. A single report satisfies domestic and export compliance.
Typically: API name, CAS number, molecular structure/formula, primary therapeutic indication, route(s) of administration, and any available internal toxicological or pharmacological data. Our team conducts all literature search and scientific assessment — no specialist knowledge required from the client side.
PDE certification aligned with